Possible Transmission of Hepatitis C Virus Infection with Intravenous Immunoglobulin
Authors: Thomas D. Schiano
Journal: Annals of Internal Medicine (1995)

Letters15 May 1995Possible Transmission of Hepatitis C Virus Infection with Intravenous ImmunoglobulinThomas D. Schiano, Somashekhar V. Bellary, and Martin BlackThomas D. SchianoTemple University, Philadelphia, PA 19140., Somashekhar V. BellaryTemple University, Philadelphia, PA 19140., and Martin BlackTemple University, Philadelphia, PA 19140.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-10-199505150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A high rate of hepatitis C virus (HCV) infection has been reported [1] in Norwegian patients with primary hypogammaglobulinemia after treatment with intravenous immunoglobulin. The preparation involved was Gammonativ (KabiVitrim), known to have been previously contaminated with a non-A, non-B hepatitis virus [2]. Similar cases have been reported in the United States with Gammagard (Baxter Health Care, Glendale, California) and possibly Polygam (American Red Cross, Washington, D.C.) [3]. We describe a patient with hypogammaglobulinemia who developed acute HCV infection after receiving Venoglobulin-I (Alpha Therapeutic Corporation, Los Angeles, California).A 60-year-old woman with hypogammaglobulinemia had been receiving immunoglobulin ...References1. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994; 331:1607-11. Google Scholar2. Iwarson S, Wejstal R, Ruttimann E. Non-A, non-B hepatitis associated with the administration of intravenous immunoglobulin—transmission studies in chimpanzees. Serodiagn Immunother. 1987; 1:261-6. Google Scholar3. Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October, 1993—June, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43:505-9. Google Scholar4. Ulrich PP, Romeo JM, Lane PK, Kelly I, Daniel LJ, Vyas GN. Detection, semi-quantification and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated aminotransferases. J Clin Invest. 1990; 86:1609-14. Google Scholar5. Uemura Y, Yang YH, Heldebrandt CM, Takechi K, Yokohama K. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang. 1994; 67:1-9. Google Scholar Author, Article, and Disclosure InformationAuthors: Thomas D. Schiano; Somashekhar V. Bellary; Martin BlackAffiliations: Temple University, Philadelphia, PA 19140. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe viral safety of intravenous immune globulinHepatic Dysfunction in a Population of Antibody-Deficient Patients: Prevalence, Aetiology and Outcome of PCR Screening for Hepatitis C and G Viruses1d Virus transmission by virus-inactivated plasma productsComplications of intravenous gammaglobulin in neuromuscular and other diseasesAverse Effects of Intravenous Immunoglobulin TherapyHepatitis C virus transmission by intravenous immunoglobulinImmunoglobulins 15 May 1995Volume 122, Issue 10Page: 802-803KeywordsHepatitis AHepatitis C virusIntravenous immunoglobulinLiver function testsNauseaPhosphatasesResearch laboratoriesSerum glutamic oxaloacetic transaminaseUpper respiratory tract infectionsViral transmission and infection ePublished: 15 August 2000 Issue Published: 15 May 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...